Affimed

ASCO: Affimed pivots to cancer combo after failing to meet monotherapy study continuation criteria
ASCO: Affimed pivots to cancer combo after failing to meet monotherapy study continuation criteria
Fierce Biotech
Affimed
ASCO 2023
AFM24
Flag link:
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
BioSpace
layoffs
Rain Oncology
Takeda
PTC Therapeutics
Affimed
Urovant Sciences
Roche
Novavax
Gossamer Bio
Bristol Myers Squibb
ADC Therapeutics
Flag link:
Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail
Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail
Fierce Biotech
Affimed
layoffs
lymphoma
Flag link:
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Clinical Trials Arena
Affimed
clinical trials
AFM283
AML
Flag link:
Ash 2022 preview – Affimed and Aptose score
Ash 2022 preview – Affimed and Aptose score
EP Vantage
ASH 2022
Affimed
Aptose Biosciences
ADI-001
CAR-T
AFM13
Flag link:
AACR 2022 – A weekend of updates yields few winners
AACR 2022 – A weekend of updates yields few winners
EP Vantage
AACR
Bicycle Therapeutics
Rubius Therapeutics
C4 Therapeutics
Zentalis
Affimed
Seagen
Astellas
Flag link:
AACR 2022 – Affimed shows that 2021 was no fluke
AACR 2022 – Affimed shows that 2021 was no fluke
EP Vantage
AACR
Affimed
AFM13
natural killer cells
Flag link:
Affimed spurs promising response numbers in NK cell study, but durability will be the big question
Affimed spurs promising response numbers in NK cell study, but durability will be the big question
Endpoints
Affimed
natural killer cell therapy
lymphoma
Flag link:
2 Biotech Companies That Might Be on Pfizer's Radar Right Now
2 Biotech Companies That Might Be on Pfizer's Radar Right Now
Motley Fool
Pfizer
M&A
Adaptimmune Therapeutics
Affimed
Flag link:
AACR 2021 – Affimed wins, Oncternal loses
AACR 2021 – Affimed wins, Oncternal loses
EP Vantage
AACR
Affimed
AFM13
Oncternal
clinical trials
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
Affimed scraps T-cell engager program, parts company with CSO
Affimed scraps T-cell engager program, parts company with CSO
Fierce Biotech
Affimed
bispecific antibodies
T-cell engager
cancer
Flag link:
Affimed and Roche ink $5bn plus cancer immunotherapy deal
Affimed and Roche ink $5bn plus cancer immunotherapy deal
Pharmaforum
Roche
Genentech
Affimed
cancer immunotherapy
drug development
Flag link:
These 5 Biotech Stocks Under $10 Are About to Break Out
These 5 Biotech Stocks Under $10 Are About to Break Out
TheStreet.com
biotech
Ardelyx
Biocryst
Affimed
Adaptimmune
Sangamo BioSciences
Flag link:
Merck teams with Affimed on immuno-oncology combo
Merck teams with Affimed on immuno-oncology combo
Fierce Biotech
Merck
Affimed
immuno-oncology
Flag link: